LIVINGSTON, N.J., March 6 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that during the month of February, dentists purchased more units of the STA(TM) System, a patented, computer-controlled local anesthetic delivery (CCLAD) system for dental injections, than in any month since its introduction in 2007.
Bob Presutti, Vice President of Sales and Marketing at Milestone, stated, "It is evident that the value proposition of the STA System has begun to resonate with dental professionals nationwide. We believe this is largely due to key refinements and more effective communication of our marketing messages which took effect shortly before the year end holidays, coupled with the growing number of highly satisfied STA users who are enthusiastically sharing their positive opinions of the STA System with their dental industry peers."
In response to surprisingly weak STA sales following its debut early last year, this past Fall Milestone initiated an in-depth review and analysis of the STA System's product positioning and messaging platform, providing for comprehensive surveying of dental practitioners and industry thought leaders. "The data compiled from our research clearly reflected that we needed to do a much better job of clarifying to the dental community that the STA System can be used for all injections, not simply the periodontal intraligamentary injection (single tooth anesthesia)," noted Presutti. "Our surveying confirmed that when giving injections to patients, many, if not most, dentists experience a similar level of fear, stress and discomfort as the patient undergoing the actual treatment. However, according to Marty Jablow, DMD, a dental practitioner in Woodbridge, New Jersey, 'The STA System allows me to begin every injection technique with significantly less stress for me and the patient.' As a consequence of these findings, we have applied what we learned and have begun to see meaningful and positive progress indicated in our overall market penetration efforts."
At the recent Chicago Dental Society's 143rd Midwinter Meeting, held in Chicago, held in late February, both Milestone and Henry Schein, Inc., the Company's distributor in the U.S. and Canada, showcased the STA System as a premier product in their respective booths. Traffic through both companies' exhibit areas remained constant and robust and resulted in a significant number of STA Systems being sold to attendees over this important three day event. In February, dentists purchased more units of the STA System than in any other month since the product launch.
The Midwinter Meeting is among the top three dental meetings in the U.S. and one of the top 10 conventions in Chicago. Each year, more than 600 exhibiting companies participate in the meeting, creating one of the largest exhibits of dental products and manufacturers in North America.
About Milestone Scientific Inc.
Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(TM) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The Single Tooth Anesthesia (STA(TM)) computer-controlled local anesthesia delivery system which uses this technology provides dentists with audible and visual signals as to in-tissue pressure. Milestone's existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's web site found at http://www.milesci.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the
timing and financial impact of the Milestone's ability to implement its
business plan, expected revenues and future success. These statements
involve a number of risks and uncertainties and are based on assumptions
involving judgments with respect to future economic, competitive and market
conditions and future business decisions, all of which are difficult or
impossible to predict accurately and many of which are beyond Milestone's
control. Some of the important factors that could cause actual results to
differ materially from those indicated by the forward-looking statements
are general economic conditions, failure to achieve expected revenue
growth, changes in our operating expenses, adverse patent rulings, FDA or
legal developments, competitive pressures, changes in customer and market
requirements and standards, and the risk factors detailed from time to time
in Milestone's periodic filings with the Securities and Exchange
Commission, including without limitation, Milestone's Annual Report on Form
10-KSB for the year ended December 31, 2006. The forward looking-statements
in this press release are based upon management's reasonable belief as of
the date hereof. Milestone undertakes no obligation to revise or update
publicly any forward-looking statements for any reason.
FOR MORE INFORMATION, PLEASE CONTACT:
Elite Financial Communications Group, LLC Dodi Handy, President and CEO, or Daniel Conway, Chief Strategy Officer
407-585-1080 or via email at email@example.com
|SOURCE Milestone Scientific Inc.|
Copyright©2008 PR Newswire.
All rights reserved